动态容积灌注CT监测胰腺癌化疗反应可行性
本研究回顾性纳入87例经病理证实的胰腺癌患者,共行141次动态容积灌注CT检查,评估化疗期间疗效监测的可行性。结果显示疾病控制组血流量显著高于进展组,纵向血流量升高与疾病控制相关。dVPCT可提供RECIST 1.1之外的功能信息,辐射剂量与常规多期增强CT相当。
要点
- 胰腺癌化疗监测中BF较高及BF纵向升高提示疾病控制,阅片时可关注灌注参数变化趋势
- dVPCT辐射剂量与常规多期增强CT相当,可用于化疗期间的动态功能评估
- 灌注参数可作为RECIST 1.1形态学评估的功能补充,但不替代RECIST判定
核心结论
- BF较高与纵向BF升高与胰腺癌全身化疗期间更好的疾病控制相关
- dVPCT可在与常规多期增强CT相当的辐射剂量下提供RECIST 1.1之外的功能信息,支持胰腺癌疗效监测
研究设计与样本
- 回顾性研究,纳入2024年12月至2026年5月连续收治的病理确诊胰腺癌患者,接受全身化疗及dVPCT检查
- 共87例患者接受141次dVPCT检查,其中36例患者贡献54个可评估扫描间期用于纵向分析
- 疗效按RECIST 1.1评估,分组为PR/SD疾病控制组与PD进展组
关键影像表现/征象
- 横断面分析中PR/SD组BF显著高于PD组(38.48 vs 26.98 mL/100mL/min,P = .013)
- 纵向分析中BF升高(估计值=12.14,P = .011)与调整后疾病控制显著相关
- BV、MTT及FEP在疾病控制组与进展组间的比较未见报告统计学差异
诊断标准与关键数值
- 疗效判定采用RECIST 1.1标准,分为PR、SD、PD,PR/SD归为疾病控制组
- BF横断面比较:PR/SD组38.48 mL/100mL/min,PD组26.98 mL/100mL/min,P = .013
- 纵向BF变化估计值=12.14,P = .011,提示BF升高与疾病控制相关
临床应用与阅片要点
- 阅片报告中可附带dVPCT灌注参数BF值及变化趋势,辅助RECIST 1.1形态学评估
- 临床怀疑进展但形态学不明确时,BF持续下降可提示治疗反应不佳,建议密切随访
- dVPCT可作为常规多期增强CT的可行替代功能成像方案,辐射剂量不额外增加负担
局限性
- 研究为回顾性单中心设计
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Perfusion CT has shown predictive value for tumor response, grade, and recurrence in pancreatic adenocarcinoma (PAC). However, its utility for real-time dynamic monitoring during chemotherapy has not been systematically evaluated. This study aimed to evaluate the feasibility of dynamic volume perfusion CT (dVPCT) for treatment response monitoring in patients with PAC.
MATERIALS AND METHODS: This retrospective study included consecutive patients with pathologically confirmed PAC who underwent systemic chemotherapy and dVPCT between December 2024 and May 2026. Treatment response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. For cross-sectional analysis, blood flow (BF), blood volume (BV), mean transit time (MTT), and flow extraction product (FEP) measured at the first response-evaluable dVPCT examination were compared between the disease-control group (partial response [PR] or stable disease [SD]) and the progressive-disease (PD) group. For longitudinal analysis, patients with serial dVPCT examinations were included, and interval changes in perfusion parameters between consecutive examinations were calculated. Linear mixed-effects models were used to evaluate longitudinal associations.
RESULTS: A total of 87 patients underwent 141 dVPCT examinations and were included in the study. Among them, 36 patients contributed 54 evaluable scan intervals for longitudinal analysis. In the cross-sectional analysis, BF was significantly higher in the PR/SD group than in the PD group (38.48 vs 26.98 mL/100mL/min, P = .013). In the longitudinal analysis, increases in BF (Estimate = 12.14, P = .011) were significantly associated with disease control after adjustment.
CONCLUSION: Higher BF and longitudinal increases in BF were associated with better disease control during systemic chemotherapy. dVPCT can provide functional information complementary to RECIST 1.1-based response assessment at a radiation dose comparable to routine multiphase contrast-enhanced CT, supporting its potential role in treatment response monitoring in PAC.
引用
- Chen, Li, Wang, et al. Feasibility of Dynamic Volume Perfusion CT for Treatment Response Monitoring in Pancreatic Adenocarcinoma. Acad Radiol. 2026. PMID: 42722556. doi:10.1016/j.acra.2026.08.112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。